Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Glob Prod Strat & Com | February 18, 2022 | February 23, 2022 |
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 03, 2026 | June 05, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP, Access, Policy & Comms | August 13, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,364 |
Ending reported balance
After 2022-02-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-18 · Exercise / conversion · Acquired 1,981 · Balance 8,243 Row 2 · 2022-02-18 · Tax withholding · Disposed 879 · Balance 7,364 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2024-02-18 | Direct | 12,519 |
Reported balance
After 2022-02-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-18 · Exercise / conversion · Disposed 1,981 · Balance 12,519 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2024-02-18 | Direct | 9,668 |
Reported balance
After 2022-02-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-18 · Other · Disposed 2,851 · Balance 9,668 F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
Beam Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.55 · Expires 2036-06-03 | Direct | 19,676 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 19,676 · Balance 19,676 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Merck & Co., Inc.
Report date August 13, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,613.127 |
Reported balance
After 2026-08-13 transaction · row 1
1 source rowRow 1 · 2026-08-13 · Sale · Disposed 10,000 · Balance 36,613.127 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 13, 2026 21:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,000 | $135.00 | $1,350,000.00 |
DisclosureSEC source: 0000310158-26-000223 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP, Access, Policy & Comms 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,613.127 Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 15,000 | $131.00 | $1,965,000.00 |
DisclosureSEC source: 0000310158-26-000213 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP, Access, Policy & Comms 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,613.127 Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 19,676 | $0.00 Strike: $29.55 | $0.00 |
DisclosureSEC source: 0001193125-26-259534 · ownership.xml · derivative · entry 1 Guindo Chirfi · CIK 0001722753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,676 Underlying: Common Stock · 19,676 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| May 05, 2026 Filed May 7, 2026 15:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 19,402 | $0.00 Strike: $113.15 | $0.00 |
DisclosureSEC source: 0000310158-26-000117 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · EVP, Access, Policy & Comms 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,402 Underlying: Common Stock · 19,402 shares Expires 2036-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 05, 2026 Filed May 7, 2026 15:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 6,628 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000117 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · EVP, Access, Policy & Comms 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,628 Underlying: Common Stock · 6,628 shares Expires 2029-05-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| April 29, 2026 Filed May 1, 2026 22:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,967 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000102 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · EVP, Access, Policy & Comms 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,935 Underlying: Common Stock · 1,967 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2026 Filed May 1, 2026 22:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 969 | $110.03 | $106,619.07 |
DisclosureSEC source: 0000310158-26-000102 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · EVP, Access, Policy & Comms 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,613.127 Read SEC document |
| April 29, 2026 Filed May 1, 2026 22:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,967 | $110.03 | $216,429.01 |
DisclosureSEC source: 0000310158-26-000102 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP, Access, Policy & Comms 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,582.127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 21:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,000 | $121.46 | $1,214,562.00 |
DisclosureSEC source: 0000310158-26-000052 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,615.127 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.4400 to $121.5150, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 21:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,000 | $118.41 | $1,184,101.00 |
DisclosureSEC source: 0000310158-26-000048 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,615.127 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.4000 to $118.4502, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 21:10 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 20,000 | $121.88 | $2,437,676.00 |
DisclosureSEC source: 0000310158-26-000034 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,615.127 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.8400 to $121.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 9,865 | $107.40 | $1,059,501.00 |
DisclosureSEC source: 0000310158-26-000014 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,615.127 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 12:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 36,903 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-25-000010 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,903 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 8/3/2023, 8/3/2024 and 8/3/2025 or, if such date was not a business day, the business day immediately thereafter. F4 · derivative.expiration_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 8/3/2023, 8/3/2024 and 8/3/2025 or, if such date was not a business day, the business day immediately thereafter. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 12:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 18,175 | $79.29 | $1,441,095.75 |
DisclosureSEC source: 0000310158-25-000010 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,233.973 Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 12:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 36,903 | $79.29 | $2,926,038.87 |
DisclosureSEC source: 0000310158-25-000010 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,408.973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 33,662 | $0.00 Strike: $17.15 | $0.00 |
DisclosureSEC source: 0000950170-25-083052 · ownership.xml · derivative · entry 1 Guindo Chirfi · CIK 0001722753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,662 Underlying: Common Stock · 33,662 shares Expires 2025-06-04 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 26,867 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013018 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,867 Underlying: Common Stock · 26,867 shares Expires 2035-04-28 F5 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 5,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013018 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,902 Underlying: Common Stock · 5,902 shares Expires 2028-04-29 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 28,158 | $97.94 | $2,757,794.52 |
DisclosureSEC source: 0001127602-25-002334 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,143.918 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 8/3/22. Performance shares were paid out at 169 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2024. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 12:22 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 39,086 | $0.00 Strike: $28.30 | $0.00 |
DisclosureSEC source: 0000950170-24-133080 · ownership.xml · derivative · entry 1 Guindo Chirfi · CIK 0001722753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,086 Underlying: Common Stock · 39,086 shares Expires 2034-12-02 F1 · derivative.exercise_date: The option vests as to one-third of the shares subject to the option on the first anniversary of the date of grant and in equal monthly installments as to the remainder of the shares for two years thereafter, subject to the Reporting Person's continued service with the Company through each vesting date. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 16:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 36,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-021690 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,903 Underlying: Common Stock · 36,901 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 8/3/2023, 8/3/2024 and 8/3/2025 or, if such date is not a business day, the business day immediately thereafter. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 16:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 17,412 | $115.20 | $2,005,862.40 |
DisclosureSEC source: 0001127602-24-021690 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,369.593 Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 16:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 36,901 | $115.20 | $4,250,995.20 |
DisclosureSEC source: 0001127602-24-021690 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,781.593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:22 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 29,297 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013976 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,297 Underlying: Common Stock · 29,297 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 36,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022015 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,804 Underlying: Common Stock · 36,901 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 8/3/2023, 8/3/2024 and 8/3/2025. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 17,989 | $105.70 | $1,901,437.30 |
DisclosureSEC source: 0001127602-23-022015 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,352.684 Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:17 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 36,901 | $105.70 | $3,900,435.70 |
DisclosureSEC source: 0001127602-23-022015 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,341.684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 34,578 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014541 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,578 Underlying: Common Stock · 34,578 shares Expires 2033-05-01 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 110,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020472 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,705 Underlying: Common Stock · 110,705 shares Expires 2025-08-03 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 8/3/2023, 8/3/2024 and 8/3/2025. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,851 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006266 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,668 Underlying: Common Stock · 2,851 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,981 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006266 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,519 Underlying: Common Stock · 1,981 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 879 | $209.79 | $184,405.41 |
DisclosureSEC source: 0001127602-22-006266 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,364 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006266 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,480 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004989 · form4.xml · derivative · entry 9 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,818 Underlying: Common Stock · 2,480 shares Expires 2023-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004989 · form4.xml · derivative · entry 8 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,298 Underlying: Common Stock · 1,336 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,395 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004989 · form4.xml · derivative · entry 7 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,395 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,261 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004989 · form4.xml · derivative · entry 6 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,395 Underlying: Common Stock · 1,261 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,189 | $214.59 | $255,147.51 |
DisclosureSEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 5 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,262 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 21, 2022. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 593 | $214.59 | $127,251.87 |
DisclosureSEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 4 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,451 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 3 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 560 | $214.59 | $120,170.40 |
DisclosureSEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,708 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004989 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:26 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 9,090 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004801 · form4.xml · derivative · entry 2 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,090 Underlying: Common Stock · 9,090 shares Expires 2025-02-10 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:47 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 3,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-001862 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,007 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 3,087 | $440.00 | $1,358,280.00 |
DisclosureSEC source: 0001127602-21-019552 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · Head of Glob Prod Strat & Com 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,919 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:11 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 14,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006982 · form4.xml · derivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2024-02-18 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:58 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,194 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006270 · form4.xml · derivative · entry 8 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,634 Underlying: Common Stock · 2,194 shares Expires 2023-02-12 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:58 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,622 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006270 · form4.xml · derivative · entry 7 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,828 Underlying: Common Stock · 1,622 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:58 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,118 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006270 · form4.xml · derivative · entry 6 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,656 Underlying: Common Stock · 2,118 shares Expires 2022-02-12 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:58 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,534 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006270 · form4.xml · derivative · entry 5 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,774 Underlying: Common Stock · 1,534 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.